<DOC>
	<DOCNO>NCT01459627</DOCNO>
	<brief_summary>OBJECTIVE OF THE STUDY : To test hypothesis 6 month DAPT ( Dual anti-platelet therapy ) second generation DES ( Drug Eluting Stent ) implantation STEMI ( ST elevation Myocardial Infarction ) inferior 12 month DAPT term clinical outcome ( composite endpoint all-cause mortality , MI , revascularization , stroke major bleed 18 month randomization ) . The trial incorporate two register study respectively safety outcome Bivalirudin Prasugrel combination Bivalirudin Ticagrelor combination 2 30 day . Finally trial design permit assessment clinical outcome primary PCI treatment STEMI new Resolute Integrity ( Medtronic Santa Rosa Ca , USA ) stent 30 day 6 month .</brief_summary>
	<brief_title>Randomized , Open Label Trial 6 Months Versus 12 Months DAPT After Drug-Eluting Stent STEMI</brief_title>
	<detailed_description>BACKGROUND OF THE STUDY : First generation DES ( Drug Eluting Stents ) significantly reduce restenosis rate compare BMS ( Bare Metal Stents ) raise concern regard high rate ongoing propensity stent thrombosis . Based concern current guideline advocate dual antiplatelet therapy ( DAPT , aspirin plus P2Y12 inhibitor ) continue 1 year DES implantation . Large registry analyze recent data challenge recommendation suggest increase mortality ( late ) stent thrombosis DAPT discontinue 6 month . STUDY DESIGN : This prospective , randomize , open-label trial test hypothesis 6 month DAPT second generation drug elute stent ( DES ) implantation STEMI inferior 12 month DAPT term clinical outcome . Patients STEMI undergo primary PCI enrol presentation . Only patient event-free ( death , MI , ST , TVR/TLR unscheduled revascularization DES first 6 month stroke bleed require discontinuation DAPT ) DAPT 6 month primary PCI randomize ( 1:1 fashion ) single ( aspirin ) versus dual antiplatelet therapy ( aspirin plus P2Y12 ) additional 6 month ( 12 month primary PCI ) assess 18 month post randomization . STUDY POPULATION : Patients 18 85 year , present STEMI undergo PCI DES implantation . INTERVENTION : Patients , event-free stil DAPT 6 month primary PCI randomize ( 1:1 fashion ) single ( aspirin ) versus dual antiplatelet therapy ( aspirin plus P2Y12 ) additional 6 month ( 12 month primary PCI ) . PRIMARY STUDY PARAMETERS/OUTCOME OF THE STUDY : DAPT STEMI trial Composite endpoint cause mortality , MI , revascularization , stroke , ST Bleeding ( TIMI ) ( net MACCE ) 18 month randomization . Registry Bivalirudin/Prasugrel Bivalirudin/Ticagrelor All cause mortality , MI , Stroke , ST bleeding ( follow BARC ) 2 30 day . Report Resolute Integrity Primary endpoint DAPT-STEMI , 30 day 6 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>STEMI patient 1885 year underwent primary PCI DES implantation . Exclusion criteria enrolment : Intolerance Aspirin , Prasugrel , Ticagrelor , Heparin , Bivalirudin , Zotarolimus Everolimus . Known bleed diathesis know coagulopathy . Planned elective surgical procedure necessitate interruption dual antiplatelet therapy first 6 month randomization . History stent thrombosis DES main leave coronary artery Active bleeding , know bleeding diathesis know coagulopathy . Planned elective surgical procedure necessitate interruption dual antiplatelet therapy first 6 month randomization . Oral anticoagulant therapy Coumadin derivates Malignancies comorbidity life expectancy le one year may result protocol noncompliance Pregnancy ( present , suspected plan ) positive pregnancy test ( woman childbearing potential negative pregnancy test mandatory ) Exclusion criterion randomization : Occurrence death , myocardial infarction , stent thrombosis target vessel lesion revascularization first 6 month inclusion . Stroke bleed require discontinuation DAPT first 6 month inclusion . Oral anticoagulant therapy Registry Exclusion criterion Intolerance Prasugrel , Ticagrelor , Bivalirudin . Known bleed diathesis know coagulopathy Report Resolute Integrity Exclusion criterion â€¢ See exclusion criterion enrollment DAPTSTEMI protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DAPT- Dual Antiplatelet Therapy</keyword>
	<keyword>STEMI</keyword>
</DOC>